CN105658228B - 结合人类补体c5的稳定多肽 - Google Patents

结合人类补体c5的稳定多肽 Download PDF

Info

Publication number
CN105658228B
CN105658228B CN201480057470.XA CN201480057470A CN105658228B CN 105658228 B CN105658228 B CN 105658228B CN 201480057470 A CN201480057470 A CN 201480057470A CN 105658228 B CN105658228 B CN 105658228B
Authority
CN
China
Prior art keywords
seq
polypeptide
amino acid
binding
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480057470.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105658228A (zh
Inventor
乔金·尼尔森
埃里克·努德林
帕特里克·斯托姆博格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Swedish Orphan Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum AB filed Critical Swedish Orphan Biovitrum AB
Publication of CN105658228A publication Critical patent/CN105658228A/zh
Application granted granted Critical
Publication of CN105658228B publication Critical patent/CN105658228B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
CN201480057470.XA 2013-08-28 2014-08-28 结合人类补体c5的稳定多肽 Active CN105658228B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1350986-4 2013-08-28
SE1350986 2013-08-28
PCT/EP2014/068282 WO2015028558A1 (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5

Publications (2)

Publication Number Publication Date
CN105658228A CN105658228A (zh) 2016-06-08
CN105658228B true CN105658228B (zh) 2020-02-07

Family

ID=51539238

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480057470.XA Active CN105658228B (zh) 2013-08-28 2014-08-28 结合人类补体c5的稳定多肽

Country Status (29)

Country Link
US (1) US9994626B2 (enExample)
EP (2) EP3038633B1 (enExample)
JP (2) JP6767865B2 (enExample)
KR (1) KR102446636B1 (enExample)
CN (1) CN105658228B (enExample)
AU (1) AU2014314222B2 (enExample)
BR (1) BR112016003142A2 (enExample)
CA (1) CA2926976C (enExample)
CY (1) CY1123732T1 (enExample)
DK (1) DK3038633T3 (enExample)
ES (1) ES2842105T3 (enExample)
HR (1) HRP20210013T1 (enExample)
HU (1) HUE052613T2 (enExample)
IL (1) IL244218A (enExample)
LT (1) LT3038633T (enExample)
MX (1) MX382140B (enExample)
MY (1) MY173804A (enExample)
NZ (1) NZ718153A (enExample)
PH (1) PH12016500371B1 (enExample)
PL (1) PL3038633T3 (enExample)
PT (1) PT3038633T (enExample)
RS (1) RS61347B1 (enExample)
RU (2) RU2020128977A (enExample)
SA (1) SA516370622B1 (enExample)
SG (1) SG11201602679VA (enExample)
SI (1) SI3038633T1 (enExample)
SM (1) SMT202100006T1 (enExample)
UA (1) UA117933C2 (enExample)
WO (1) WO2015028558A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58503B1 (sr) 2012-02-20 2019-04-30 Swedish Orphan Biovitrum Ab Publ Polipeptidi koji se vezuju za humani komplement c5
MX367423B (es) * 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
LT3038633T (lt) * 2013-08-28 2021-03-25 Ipc Research, Llc Stabilūs polipeptidai, kurie rišasi prie žmogaus komplemento c5
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
CN117327188A (zh) 2017-07-11 2024-01-02 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
WO2022171892A1 (en) * 2021-02-15 2022-08-18 Affibody Ab New her2-binding polypeptide
KR20240134857A (ko) * 2021-11-01 2024-09-10 아이피씨 리써치, 엘엘씨 C5-결합 단백질 투여
WO2024227886A1 (en) 2023-05-02 2024-11-07 Mebrahtu Aman Bispecific binding molecule

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075507A1 (en) * 2004-02-09 2005-08-18 Affibody Ab Amyloid beta peptide binding polypeptide
WO2009077175A1 (en) * 2007-12-19 2009-06-25 Affibody Ab Polypeptide derived from protein a and able to bind pdgf
CN103003296A (zh) * 2010-07-09 2013-03-27 阿菲博迪公司 多肽
CN104114574A (zh) * 2012-02-20 2014-10-22 瑞典孤儿比奥维特鲁姆有限公司 结合人补体c5的多肽

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CA2424379C (en) 2000-10-10 2013-10-01 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
CN100391537C (zh) 2001-08-17 2008-06-04 建南德克公司 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
EP1667702A2 (en) 2003-09-10 2006-06-14 Baxter International Inc., Baxter Healthcare Corp. Peptides that inhibit complement activation
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
DK1991275T3 (en) * 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
HUE066795T2 (hu) * 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
US8937153B2 (en) 2007-07-31 2015-01-20 Affibody Ab Compositions, methods and uses
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
MX2011001371A (es) 2008-08-05 2011-06-16 Novartis Ag Composiciones y metodos para anticuerpos que se dirigen a la proteina de complementos c5.
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
EP2935335B1 (en) 2012-12-19 2020-10-28 Affibody AB New polypeptides
MX367423B (es) * 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
LT3038633T (lt) * 2013-08-28 2021-03-25 Ipc Research, Llc Stabilūs polipeptidai, kurie rišasi prie žmogaus komplemento c5

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075507A1 (en) * 2004-02-09 2005-08-18 Affibody Ab Amyloid beta peptide binding polypeptide
WO2009077175A1 (en) * 2007-12-19 2009-06-25 Affibody Ab Polypeptide derived from protein a and able to bind pdgf
CN103003296A (zh) * 2010-07-09 2013-03-27 阿菲博迪公司 多肽
CN104114574A (zh) * 2012-02-20 2014-10-22 瑞典孤儿比奥维特鲁姆有限公司 结合人补体c5的多肽

Also Published As

Publication number Publication date
PH12016500371A1 (en) 2016-05-02
EP3811961B1 (en) 2025-08-20
SA516370622B1 (ar) 2018-12-23
PL3038633T3 (pl) 2021-07-19
UA117933C2 (uk) 2018-10-25
SG11201602679VA (en) 2016-05-30
JP6767865B2 (ja) 2020-10-14
EP3038633B1 (en) 2020-10-14
NZ718153A (en) 2022-05-27
MY173804A (en) 2020-02-24
HUE052613T2 (hu) 2021-05-28
LT3038633T (lt) 2021-03-25
KR102446636B1 (ko) 2022-09-23
US9994626B2 (en) 2018-06-12
AU2014314222A1 (en) 2016-04-21
BR122023020080A2 (pt) 2023-12-26
CA2926976C (en) 2023-11-28
JP2016529270A (ja) 2016-09-23
CN105658228A (zh) 2016-06-08
HK1225656A1 (en) 2017-09-15
RU2016111115A3 (enExample) 2018-04-25
MX382140B (es) 2025-03-13
CA2926976A1 (en) 2015-03-05
RU2020128977A (ru) 2021-11-30
SI3038633T1 (sl) 2021-05-31
WO2015028558A1 (en) 2015-03-05
PH12016500371B1 (en) 2016-05-02
RS61347B1 (sr) 2021-02-26
JP2020172505A (ja) 2020-10-22
EP3811961A1 (en) 2021-04-28
US20160311870A1 (en) 2016-10-27
DK3038633T3 (da) 2021-01-11
MX2016002397A (es) 2016-09-08
SMT202100006T1 (it) 2021-03-15
KR20160048121A (ko) 2016-05-03
IL244218A (en) 2017-11-30
IL244218A0 (en) 2016-04-21
RU2016111115A (ru) 2017-10-03
RU2733897C2 (ru) 2020-10-09
AU2014314222B2 (en) 2018-05-24
BR112016003142A2 (pt) 2017-10-17
ES2842105T3 (es) 2021-07-12
HRP20210013T1 (hr) 2021-04-02
EP3038633A1 (en) 2016-07-06
PT3038633T (pt) 2021-01-14
CY1123732T1 (el) 2021-10-29

Similar Documents

Publication Publication Date Title
CN105658228B (zh) 结合人类补体c5的稳定多肽
CN109641046B (zh) 单链可变片段cd3结合蛋白质
CA2468583C (en) Self-assembling multimeric binding complexes derived from ab5 toxin family members
CN102686611A (zh) 与“渐进性糖化终产物受体”结合的多肽以及包括所述多肽的组合物和方法
RS63149B1 (sr) Insertabilni varijabilni fragmenti antitela i modifikovani a1-a2 domeni nkg2d liganada
CN105473606A (zh) 具有突变的支架的结合多肽
US20210355180A1 (en) Alzheimer abeta peptide binding polypeptide
JP2023551481A (ja) 標的分子の選択的枯渇のための組成物及び方法
HK40050539A (en) Stable polypeptides binding to human complement c5
HK40050539B (en) Stable polypeptides binding to human complement c5
CN116262784A (zh) 增强FcRn亲和力的Fc变体
HK1225656B (en) Stable polypeptides binding to human complement c5
BR122023020080B1 (pt) Polipeptídeos e compostos de ligação a c5 do complemento humano
KR20200033807A (ko) 전압-게이팅된 칼슘 채널 보조 서브유닛 α2δ 및 이의 용도
CN106084026B (zh) 肿瘤血管内皮细胞标志物8突变体、其融合蛋白及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant